Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024.
Murphy R, Moots RJ, Brogan P, Çelik AF, Clement-Jones M, Coulson I, Croft AP, Crozier S, Forrest L, Harrold J, Higgins S, Jawad ASM, Kalra S, Khan SS, McKee H, Pain CE, Petrushkin H, Poveda-Gallego A, Setterfield J, Sharma P, West R, Wlodek C, Hashme M, Manounah L, Mohd Mustapa MF, Constantin AM. Murphy R, et al. Among authors: kalra s. Br J Dermatol. 2024 Oct 17;191(5):e8-e25. doi: 10.1093/bjd/ljae263. Br J Dermatol. 2024. PMID: 39253835 No abstract available.
The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
Young CA, Mills R, Langdon D, Sharrack B, Majeed T, Kalra S, Footitt D, Rog D, Harrower T, Nicholas R, Woolmore J, Thorpe J, Hanemann CO, Ford H, Paling D, Ellis C, Palace J, Constantinescu C, Tennant A. Young CA, et al. Among authors: kalra s. J Neurol Sci. 2022 May 15;436:120188. doi: 10.1016/j.jns.2022.120188. Epub 2022 Feb 18. J Neurol Sci. 2022. PMID: 35303502
Prevalence, treatment and correlates of depression in multiple sclerosis.
Young CA, Langdon D, Rog D, Chhetri SK, Tanasescu R, Kalra S, Webster G, Nicholas R, Ford HL, Woolmore J, Paling D, Tennant A, Mills R; TONiC study group. Young CA, et al. Among authors: kalra s. Mult Scler Relat Disord. 2024 Jul;87:105648. doi: 10.1016/j.msard.2024.105648. Epub 2024 Apr 26. Mult Scler Relat Disord. 2024. PMID: 38713965 Free article.
Measuring coping in multiple sclerosis: The Coping Index-MS.
Young CA, Mills RJ, Langdon D, Rog DJ, Sharrack B, Kalra S, Majeed T, Footit D, Harrower T, Nicholas RS, Ford HL, Woolmore J, Johnstone C, Thorpe J, Paling D, Ellis C, Hanneman CO, Tennant A. Young CA, et al. Among authors: kalra s. Mult Scler. 2022 Dec;28(14):2274-2284. doi: 10.1177/13524585221114004. Epub 2022 Aug 24. Mult Scler. 2022. PMID: 36000480
Measuring disability in multiple sclerosis: the WHODAS 2.0.
Young CA, Rog DJ, Sharrack B, Constantinescu C, Kalra S, Harrower T, Langdon D, Tennant A, Mills RJ; Trajectories of Outcome in Neurological Conditions (MS) Study Group. Young CA, et al. Among authors: kalra s. Qual Life Res. 2023 Nov;32(11):3235-3246. doi: 10.1007/s11136-023-03470-6. Epub 2023 Aug 17. Qual Life Res. 2023. PMID: 37589773 Free PMC article.
Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.
Young CA, Rog DJ, Sharrack B, Tanasescu R, Kalra S, Harrower T, Tennant A, Mills RJ; Trajectories of Outcome in Neurological Conditions-MS Study Group. Young CA, et al. Among authors: kalra s. Neurol Sci. 2024 May;45(5):2181-2189. doi: 10.1007/s10072-023-07155-3. Epub 2023 Nov 17. Neurol Sci. 2024. PMID: 37976012 Free PMC article.
Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
Rog D, Brownlee W, Carod-Artal FJ, Kalra S, Barker N, Lowndes C, Pendlebury J, Leclerc S, Amin A, Ashton L, Evans H, De Cock E. Rog D, et al. Among authors: kalra s. Mult Scler Relat Disord. 2024 Feb;82:105380. doi: 10.1016/j.msard.2023.105380. Epub 2023 Dec 13. Mult Scler Relat Disord. 2024. PMID: 38183696 Free article.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. Among authors: kalra s. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article. Clinical Trial.
2,214 results